AIM ImmunoTech Inc. (NYSE American: AIM) will participate in a Virtual Investor Closing Bell Event on Thursday, February 19, 2026, at 4:00 PM ET. The event will include a live video webcast featuring Tom Equels, Chief Executive Officer of AIM ImmunoTech, who will discuss the company’s clinical and regulatory strategy for its lead drug Ampligen, particularly its role in the ongoing DURIPANC clinical trial in collaboration with AstraZeneca. The trial combines Ampligen with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) for the treatment of metastatic pancreatic cancer. The live webcast will be available on the Events page of the company's website (aimimmuno.com), with a replay accessible two hours after the live presentation for 90 days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653233-en) on February 12, 2026, and is solely responsible for the information contained therein.